CENTOGENE N.V., Am Strande 7, 18055 Rostock, Germany
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
United States
April 23, 2020
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen,
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Centogene N.V. made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on April 23, 2020. The disclosure can be found under the heading Miscellaneous Disclosure under Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRA) in the Annual Report on Form 20-F.
Respectfully submitted,
/s/ Arndt Rolfs |
|
Arndt Rolfs |
|
Chief Executive Officer |
|
Centogene N.V. |
|
CENTOGENE N.V. |
Management Board: |
Statutory seat: |
Am Strande 7 |
Prof. Dr. Arndt Rolfs (CEO) |
Amsterdam, registered with the Kamer van |
18055 Rostock, Germany |
Richard Stoffelen (CFO) |
Koophandel (Netherlands) under 72822872 |
Tel: +49 (0)381 80 113 - 400 |
Dr. Volkmar Weckesser (CIO) |
Bank account details: |
Fax: +49 (0)381 80 113 - 401 |
Dr. Dirk Ehlers (COO) |
Bank: Commerzbank AG |
Email: info@centogene.com |
Supervisory Board: |
IBAN: DE60130400000108866500 |
www.centogene.com |
Dr. Flemming Ornskov (Chairman) |
BIC: COBADEFFXXX |